Please login to the form below
Aimvog
This page shows the latest Aimvog news and features for those working in and with pharma, biotech and healthcare.
CGRP migraine drugs need prior approval for use, recommends ICER
Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors
Latest news
-
Novartis, Amgen set low price for first CGRP migraine drug
Aimovig has a list price of $6,900 per year
-
Allergan’s oral migraine drug closer to US filing
New data keeps Allergan ahead of rival Biohaven
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
